A 39-year-old woman was diagnosed with Stage IV adenocarcinoma of the left lung, which tested negative for EGFR, ALK, and ROS-1 mutations, while showing a 2% expression of PD-L1 and an ERBB2 mutation. This evidence concerns the gene ALK and adenocarcinoma.